In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Mounjaro and Zepbound helped drive the US drugmaker's total Q2 revenue to $15.56bn, up 38% from the same period last year. In a conference call, Eli Lilly CEO David Ricks acknowledged the role the two ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

Eli Lilly and Company (NYSE:LLY) is one of the Reddit Stocks with the Highest Upside Potential. On August 7, the company ...

Eli Lilly said the guidance increase was primarily driven by the strong performance of Mounjaro and Zepbound and comes in part due to "improved clarity" into the company's production expansions ...

(RTTNews) - Eli Lilly and Company (LLY) announced that the highest approved doses of Zepbound —12.5 mg and 15 mg — will soon be available in single-dose vials for $499 per month through ...